Thiard News@F4F

@newsen.bsky.social

1 week ago

ADC Therapeutics Unveils New Employee Inducement Grant to Strengthen Talent Pool ADC Therapeutics announced a new employee inducement grant, issuing stock options to enhance motivation and support performance excellence.

ADC Therapeutics Unveils New Employee Inducement Grant to Strengthen Talent Pool #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

1 month ago

ADC Therapeutics Announces 2025 Financial Outcomes and Future Directions in ADCT Operations ADC Therapeutics reveals its financial and operational outlook for 2025, highlighting new drug trials and strategic partnerships aimed at enhancing revenue and treatment solutions.

ADC Therapeutics Announces 2025 Financial Outcomes and Future Directions in ADCT Operations #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #DLBCL

Thiard News@F4F

@newsen.bsky.social

1 month ago

ADC Therapeutics Offers Stock Options to New Employees Under Inducement Plan ADC Therapeutics has announced stock option grants to new hires as part of its induction strategy, aimed to enhance employee motivation and retention.

ADC Therapeutics Offers Stock Options to New Employees Under Inducement Plan #stock_options #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne

Thiard News@F4F

@newsen.bsky.social

1 month ago

ADC Therapeutics Enhances Flexibility with Amended Royalty Financing Agreement ADC Therapeutics announces a revised financing agreement with HealthCare Royalty to boost strategic flexibility and support growth for ZYNLONTA.

ADC Therapeutics Enhances Flexibility with Amended Royalty Financing Agreement #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #HealthCare_Royalty

Thiard News@F4F

@newsen.bsky.social

2 months ago

ADC Therapeutics Announces Grants for New Employees Under Inducement Plan ADC Therapeutics has granted share options to new employees as part of its Inducement Plan, aiming to enhance performance and commitment within the company.

ADC Therapeutics Announces Grants for New Employees Under Inducement Plan #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

2 months ago

Pomerantz Law Firm Launches Investigation into ADC Therapeutics SA for Possible Securities Fraud Pomerantz LLP is investigating ADC Therapeutics SA on behalf of investors. The probe focuses on potential securities fraud and unlawful business practices linked to the company.

Pomerantz Law Firm Launches Investigation into ADC Therapeutics SA for Possible Securities Fraud #United_States #New_York #Pomerantz_LLP #ADC_Therapeutics #ZYNLONTA

Thiard News@F4F

@newsen.bsky.social

3 months ago

ADC Therapeutics Releases Preliminary Revenue Estimates for 2025 and Clinical Updates Discover ADC Therapeutics' preliminary performance metrics for 2025, including significant developments and future clinical trials related to ZYNLONTA.

ADC Therapeutics Releases Preliminary Revenue Estimates for 2025 and Clinical Updates #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #LOTIS_trials

Thiard News@F4F

@newsen.bsky.social

3 months ago

ADC Therapeutics to Showcase Innovations at J.P. Morgan Healthcare Conference 2026 ADC Therapeutics will present at the upcoming J.P. Morgan Healthcare Conference 2026, highlighting advancements in antibody-drug conjugates and patient treatment.

ADC Therapeutics to Showcase Innovations at J.P. Morgan Healthcare Conference 2026 #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

3 months ago

ADC Therapeutics Awards Grant to New Employee Supporting Growth Initiatives ADC Therapeutics has announced a new employee inducement grant allowing for the purchase of 6,000 common shares, enhancing their strategic workforce.

ADC Therapeutics Awards Grant to New Employee Supporting Growth Initiatives #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

4 months ago

ADC Therapeutics Expands Workforce with Inducement Grants to New Hires ADC Therapeutics has announced the granting of stock options to several new employees as part of their induction plan. This strategic move aims to enhance motivation and retention.

ADC Therapeutics Expands Workforce with Inducement Grants to New Hires #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

5 months ago

ADC Therapeutics Provides Financial and Operational Insights for Q3 2025 ADC Therapeutics has released its financial results for Q3 2025, showcasing progress in clinical trials and increased funding in operations.

ADC Therapeutics Provides Financial and Operational Insights for Q3 2025 #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #LOTIS_trials

Thiard News@F4F

@newsen.bsky.social

5 months ago

ADC Therapeutics to Showcase Innovative Developments at November Investor Conferences ADC Therapeutics will participate in three investor conferences this November, highlighting advancements in antibody drug conjugates and future prospects.

ADC Therapeutics to Showcase Innovative Developments at November Investor Conferences #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

6 months ago

ADC Therapeutics Secures $60 Million Through Private Placement Financing for Growth ADC Therapeutics recently announced a $60 million private investment in public equity to strengthen its balance sheet and fund the expansion of ZYNLONTA.

ADC Therapeutics Secures $60 Million Through Private Placement Financing for Growth #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #Private_Placement

Thiard News@F4F

@newsen.bsky.social

6 months ago

ADC Therapeutics Introduces Inducement Grants for New Employees to Boost Engagement and Performance ADC Therapeutics has launched a new inducement plan, granting stock options to four new hires. This initiative aims to enhance employee motivation and company success.

ADC Therapeutics Introduces Inducement Grants for New Employees to Boost Engagement and Performance #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

7 months ago

ADC Therapeutics Introduces Grant Program for New Employees to Enhance Engagement and Performance ADC Therapeutics has launched a new inducement grant program for employees to boost performance and commitment. This initiative highlights their strategic growth ambitions in the competitive market.

ADC Therapeutics Introduces Grant Program for New Employees to Enhance Engagement and Performance #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

7 months ago

ADC Therapeutics Announces Participation at 2025 Cantor Global Healthcare Conference ADC Therapeutics is set to showcase its advancements at the upcoming 2025 Cantor Global Healthcare Conference, led by CEO Ameet Mallik. Learn more about their innovative approaches to cancer treatment.

ADC Therapeutics Announces Participation at 2025 Cantor Global Healthcare Conference #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

8 months ago

ADC Therapeutics Reports Impressive Results and Financial Updates for Q2 2025 ADC Therapeutics has released its Q2 2025 financial results, showcasing significant operational advancements and strong clinical data for its product ZYNLONTA®.

ADC Therapeutics Reports Impressive Results and Financial Updates for Q2 2025 #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #glofitamab

Thiard News@F4F

@newsen.bsky.social

8 months ago

ADC Therapeutics Expands Workforce with New Inducement Grants for Employees In an effort to attract top-level talent, ADC Therapeutics has granted stock options to new employees, reinforcing its commitment to growth and innovation.

ADC Therapeutics Expands Workforce with New Inducement Grants for Employees #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

9 months ago

ADC Therapeutics Expands Team with New Employee Stock Incentive Grant ADC Therapeutics has announced a grant of stock options to a new employee, aimed at boosting motivation and performance within the company.

ADC Therapeutics Expands Team with New Employee Stock Incentive Grant #stock_options #ADC_Therapeutics #ZYNLONTA

Thiard News@F4F

@newsen.bsky.social

10 months ago

ADC Therapeutics Secures $100 Million in Private Placement, Paving the Way for Future Growth ADC Therapeutics has successfully completed a $100 million private placement, extending its financial runway into 2028 while focusing on its key product ZYNLONTA.

ADC Therapeutics Secures $100 Million in Private Placement, Paving the Way for Future Growth #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #Private_Placement

Thiard News@F4F

@newsen.bsky.social

10 months ago

ADC Therapeutics Incentivizes New Employees with Stock Options Grants ADC Therapeutics has announced the granting of stock options to new employees, aiming to boost motivation and performance under its Inducement Plan.

ADC Therapeutics Incentivizes New Employees with Stock Options Grants #stock_options #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne

Thiard News@F4F

@newsen.bsky.social

11 months ago

ADC Therapeutics Set to Showcase Innovations at Notable Investor Conferences ADC Therapeutics announces its participation in two prestigious investor conferences featuring insights from CEO Ameet Mallik regarding advancements in ADC technology.

ADC Therapeutics Set to Showcase Innovations at Notable Investor Conferences #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #Ameet_Mallik

Thiard News@F4F

@newsen.bsky.social

11 months ago

ADC Therapeutics Releases Promising Q1 2025 Financial Results and LOTIS-7 Clinical Updates ADC Therapeutics showcases strong Q1 2025 financial results and highlights publication of LOTIS-7 clinical trial data, suggesting a bright future.

ADC Therapeutics Releases Promising Q1 2025 Financial Results and LOTIS-7 Clinical Updates #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #LOTIS-7

Thiard News@F4F

@newsen.bsky.social

1 year ago

ADC Therapeutics Implements Employee Stock Grants in Strategic Inducement Plan ADC Therapeutics has issued stock option grants to new employees as part of a strategic inducement plan to drive performance and growth.

ADC Therapeutics Implements Employee Stock Grants in Strategic Inducement Plan #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

1 year ago

ADC Therapeutics Releases Financial Results for Q4 and Full Year 2024, Highlights Promising Clinical Data ADC Therapeutics has shared its financial results for Q4 and the whole of 2024, showcasing significant clinical achievements and updates on ongoing trials.

ADC Therapeutics Releases Financial Results for Q4 and Full Year 2024, Highlights Promising Clinical Data #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #DLBCL

Thiard News@F4F

@newsen.bsky.social

1 year ago

ADC Therapeutics Expands Workforce with New Employee Induction Grants ADC Therapeutics has announced new options grants for three employees as part of its Inducement Plan to enhance motivation and performance.

ADC Therapeutics Expands Workforce with New Employee Induction Grants #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #antibody_drug_conjugates

Thiard News@F4F

@newsen.bsky.social

1 year ago

ADC Therapeutics Implements Incentive Plan for New Employees with Stock Options ADC Therapeutics has introduced an inducement plan for new staff, granting options for 20,000 shares. This initiative aims to boost company growth.

ADC Therapeutics Implements Incentive Plan for New Employees with Stock Options #stock_options #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne

Thiard News@F4F

@newsen.bsky.social

1 year ago

ADC Therapeutics Completes Enrollment for Phase 3 Trial of ZYNLONTA® in Combination for DLBCL Treatment ADC Therapeutics has concluded participant enrollment for a crucial Phase 3 trial studying ZYNLONTA® combined with Rituximab for treating DLBCL. This marks a significant advancement in oncological therapies.

ADC Therapeutics Completes Enrollment for Phase 3 Trial of ZYNLONTA® in Combination for DLBCL Treatment #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #DLBCL

Thiard News@F4F

@newsen.bsky.social

1 year ago

ADC Therapeutics Reveals Promising Results from LOTIS-7 Trial of ZYNLONTA for DLBCL Treatment Exciting initial findings from the LOTIS-7 trial show ZYNLONTA’s potential in treating relapsed DLBCL, combining with glofitamab to achieve exceptional response rates.

ADC Therapeutics Reveals Promising Results from LOTIS-7 Trial of ZYNLONTA for DLBCL Treatment #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #bispecific_antibody

Thiard News@F4F

@newsen.bsky.social

1 year ago

Promising Results from ZYNLONTA and Rituximab for Follicular Lymphoma Patients Presented in The Lancet Haematology ADC Therapeutics shares groundbreaking data from a study on ZYNLONTA combined with Rituximab for treating relapsed follicular lymphoma, showing impressive outcomes.

Promising Results from ZYNLONTA and Rituximab for Follicular Lymphoma Patients Presented in The Lancet Haematology #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #Rituximab